Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2020-02-26 Capital/Financing Update
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Prospectus Supplement to Prospectus dated June 21, 2019
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "Prospectus Supplement to Prospectus dated June 21, 2019" and details an offering of ordinary shares and placement agent warrants. It discusses the offering price, placement agent fees, risk factors, and includes a detailed Table of Contents typical of offering documents filed with the SEC (Securities and Exchange Commission). This structure, focusing on the sale of securities, aligns directly with the definition of a document related to capital raising or financing activities, specifically a prospectus supplement. While it is a formal filing, it is not a standard periodic report (10-K, IR) or a general announcement (RPA/RNS). It is a specific document used for capital raising. Reviewing the definitions: - 10-K: No, this is not an annual report. - ER/IR: No, this is not an earnings release or interim report. - RPA/RNS: While it is a filing, the content is highly specific to a securities offering, making a more specific code preferable. - CAP (Capital/Financing Update): This category best fits a prospectus supplement detailing the terms of a share offering and associated warrants. Therefore, the classification is Capital/Financing Update (CAP).
2020-02-26 English
Prospectus Supplement to Prospectus dated June 21, 2019
Report Publication Announcement Classification · 1% confidence The document is a short filing (1871 characters) issued to the Israel Securities Authority and the Tel Aviv Stock Exchange. It explicitly states, "Attached hereto is a report on *ea119014-424b5_enlivextheASFILED_isa.pdf*". This structure—a brief announcement stating that a formal report is attached or published, rather than containing the full report content itself—fits the definition of a Report Publication Announcement (RPA). It is not a specific report type like 10-K, ER, or IR, but rather the notification of its release.
2020-02-26 English
Announces $8.0 Million Registered Direct Offering
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a registered direct offering of ordinary shares by Enlivex Therapeutics. It details the amount of capital being raised ($8.0 million), the purpose of the funds, and the involvement of a placement agent. This falls under the category of company fundraising and financing activities.
2020-02-25 English
Announces $8.0 Million Registered Direct Offering
Report Publication Announcement Classification · 1% confidence The document is very short (1783 characters) and explicitly states, "Attached hereto is a report on *6-k* *pressrelease25022020_isa.pdf*". This structure—a brief filing announcing the publication of a specific external report (in this case, a Form 6-K, which is a general SEC filing for foreign private issuers)—fits the definition of a Report Publication Announcement (RPA). It is not the full 6-K report itself, but the announcement of its release. Since RPA is a defined category for such announcements, it is preferred over the general fallback RNS.
2020-02-25 English
Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934," which corresponds to a Form 6-K filing. Form 6-K is used by foreign private issuers to report material information to the SEC, often mirroring the content of a press release. The content itself is a press release dated February 24, 2020, announcing plans to increase manufacturing capacity for AllocetraTM in preparation for potential COVID-19 treatment. Since Form 6-K is a specific SEC filing type not explicitly listed in the provided codes (AGM-R, 10-K, AR, etc.), and it functions as a general regulatory disclosure, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a mandatory filing to the SEC that doesn't fit the other specific categories like Earnings Release (ER) or Interim Report (IR). However, given the context of SEC filings, Form 6-K is a standard regulatory submission. If 'RNS' is strictly for miscellaneous non-SEC filings, 'RNS' is still the best fit among the options for a general, non-periodic SEC report that isn't a 10-K or proxy statement. Since the document is a formal SEC filing (Form 6-K) containing material news, and 'RNS' is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' RNS is the correct classification here.
2020-02-24 English
Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure
Report Publication Announcement Classification · 1% confidence The document is very short (1765 characters) and explicitly states, "Attached hereto is a report on *6-k* *6K_isa.pdf*". This structure indicates that the document itself is an announcement about an attached or linked report (a 6-K filing, which is an SEC filing for foreign private issuers, often used for material events). According to Rule 2 (The "MENU VS MEAL" Rule), when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA). Since this is a regulatory filing announcement, RPA is the most appropriate specific category, although RNS could also apply as a fallback. Given the explicit mention of publication/attachment, RPA is preferred over the general RNS.
2020-02-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.